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-globulins or rheumatoid factors (RF) were first
described in the early 1940s. They are present in 
 
.
 
70%
of patients with rheumatoid arthritis (RA) and high titers
are associated with severe disease, but they also appear in a
large number of other diseases including viral, bacterial,
and parasitic infections (1). In spite of their wide spread oc-
currence, it is still a puzzle how or why RF are generated.
 
RF come in two varieties. Low affinity RF (K
 
d
 
 of
 
z
 
10
 
2
 
5
 
 M) are IgM natural antibodies with specificity for
IgG-Fc determinants and cross-reactivity with other au-
toantigens, i.e., polyreactivity. They are produced by CD5
 
1
 
B cells in normal subjects (2). Frequently they are IgM 
 
k
 
antibodies and use selected germline V genes for both H
and L chains. This is why they share cross-reactive idio-
types, as discovered by Kunkel et al. in the 1970s (3). These
antibodies are typically T cell independent. They are simi-
lar to the RF produced in response to polyclonal B cell ac-
tivation by EBV (4) or LPS (5, 6). B cells producing these
RF appear to be susceptible to malignant transformation as
the RF-associated V genes are frequently expressed in low
grade chronic B lymphoproliferative diseases such as chronic
lymphocytic leukemia, Waldenstrom’s macroglobulinemia,
mixed cryoglobulinemia and lymphoma associated with
Sjögren’s disease. This may be due to constitutive expres-
sion of STAT3 in B1 cells (7). The RF-associated V genes
are also over-expressed by human fetal B cells (8, 9), per-
haps consistent with a role for low affinity RF in neonates
that lack a mature humoral immune system. In spite of the
low affinity, the multivalency of IgM RF allows excellent
agglutination of latex particles or red blood cells, and pre-
sumably also microbial organisms, in vivo, that are coated
with specific IgG antibodies. The presence of IgM RF can
lead to large immune complexes with lattice formation, that
are poorly soluble and rapidly removed by the mononuclear
phagocyte system (10).
High affinity RF (K
 
d
 
 of 
 
z
 
10
 
2
 
7
 
 M) can be IgM, IgG,
IgA, or IgE antibodies. RA patients may have high titers of
this type of RF. Their production is T cell dependent.
These antibodies often do not share the V genes used by
the low affinity RF (11). They have undergone affinity mat-
uration, as there are multiple somatic mutations in the V
genes, and are therefore produced by antigen driven B cells.
These RF bind most avidly to the Ig isotype which stimu-
lated their production. In RA, RF are particularly abun-
dant in the synovium. In some reports the dominant speci-
ficity of synovial RF is for IgG3-Fc (12), implying that the
immune complexes that stimulated their local production
contained IgG3.
Experimental production of RF has been described with
either polyclonal B cell stimulation or immunizations with
immune complexes. In mice treated with LPS, high titers
of T-independent RF are produced (5, 6). In humans,
EBV is a polyclonal B cell activator, and in vitro transfor-
mation with EBV results in the production of IgM RF (2,
4). In contrast, immunizations with immune complexes re-
sult in T-dependent high-affinity RF. Thus, a mixture of a
complex multivalent antigen, 
 
Limulus polyphemus
 
 hemocya-
nin conjugated with a hapten (
 
p
 
-azophenylarsonate), and
IgG1 antibody to the hapten, results in IgM anti-IgG1-Fc
RF. In addition, when an IgG2a antibody specific for the
hapten has been used, the IgM RF is specific for IgG2a-Fc
(13). The RF response does not occur in nude mice and is
therefore T-dependent, unlike the RF induced by LPS.
Similar results are obtained with TNP-conjugated transfer-
rin or KLH, which are also multivalent antigens, and the
importance of saturation of the immune complex with an-
tibody has been shown, as well as the requirement for
primed T cells (14). Relevant to RA, the multivalent anti-
gen, collagen type II, complexed with a monoclonal anti-
collagen II IgG2a antibody, induces IgG anti-IgG-Fc RF in
mice (15). One such RF, immortalized as a hybridoma, has
unusual dual reactivity as an RF and an antiidiotype against
the anticollagen mAb used for immunization. It is common
to see antiidiotypic antibodies and high-affinity RF in sec-
ondary immune responses. Both represent antibodies against
a self antibody and are thought to play a role in regulation
of the immune response, but they may also participate in
clearance of immune complexes (1).
In this issue of 
 
The Journal of Experimental Medicine
 
, Fehr
et al. describe a novel way to generate antibodies against
antibodies (16). They use UV-inactivated vesicular stomati-
tis virus (VSV). The envelope of this virus is densely packed
with the single viral glycoprotein, VSV-G (17). The anti-
genic epitopes are regularly spaced, 5–10 nM apart, in this
rigid paracrystalline membrane (18). The authors have pre-
viously suggested that some viruses like VSV with structur-
ally rigid envelopes, unlike the fluid membranes of eukary-
otic cells where membrane proteins have lateral mobility,
are associated with production of T cell–independent anti-
bodies (18). To induce antiantibodies, they coat VSV with sat-
urating amounts of monoclonal IgM anti-VSV-G antibodies
and immunize BALB/c mice twice over 14 d. IgG anti-
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IgM antibody was detected at serum titers up to 1:20,480.
These antiimmunoglobulins were antiidiotypic. They were
not elicited if IgG anti-VSV antibodies were used instead of
the IgM, nor if recombinant, soluble VSV-G protein was
expressed as micelles and then complexed with IgM anti-
VSV-G, suggesting a requirement for a high concentration
of VSV-G in the rigid paracrystalline envelope of VSV.
IgM anti-VSV-G complexed using a rat anti-
 
k
 
 antibody
also failed to induce antiimmunoglobulins. In A/J mice of
IgM
 
e
 
 haplotype immunized in the same way, the antiim-
munoglobulins were allotypic as the immunizing IgM anti-
VSV-G is of BALB/c origin (IgM
 
a
 
). In both systems, these
IgG antiimmunoglobulins could not be raised in CD4-
depleted or nude mice, i.e., they were T-dependent re-
sponses.
Similar immunizations were performed with UV-inacti-
vated bacteria coated with anti-LPS IgG2a or IgG2b anti-
bodies specific for the highly repetitive 
 
O
 
-linked external
sugar chains of LPS which carry the immunogenic epitopes.
Because LPS is also tightly packed on the outer cell wall of
bacteria, this is considered a rigid structure. 
 
Pseudomonas
aeruginosa
 
 coated with syngeneic IgG2b anti-LPS stimulated
the production of IgG anti-IgG2b RF. These were not
seen in LPS nonresponder C3H/HeJ mice, but bacteria
alone, without complexed anti-LPS antibody, did not stim-
ulate RF production. Whether this was a T cell–dependent
response was not tested. Finally, 
 
Salmonella typhi
 
 coated
with IgG2a anti-LPS (of NZB origin) stimulated produc-
tion of allospecific IgG anti-IgG recognizing only NZB IgGs.
These data provide a direct link between exposure to in-
tact virus or bacteria and the development of antiimmuno-
globulins. They suggest that the occurrence of antiimmu-
noglobulins in vivo may be related to chronic exposure to
microbes that are particularly immunogenic due to the
high concentration of epitopes on their surface. In the case
of a low grade chronically productive infection (HIV, her-
pesviruses, untreated bacterial endocarditis), the microbes
would be complexed with host antibodies, and this appar-
ently provides an excellent stimulus for the production of
anti-
 
g
 
-globulins.
The rules for RF production by complexed viruses are
clearly not the same as those for T-independent responses
(18). RF were induced only in the 
 
Pseudomonas
 
 model by
Fehr et al. (16). Polyclonal B cell stimulation by LPS was
required. In addition, stimulation with the complexed IgG2b
anti-LPS antibody was also necessary. This is of interest be-
cause it raises the question of whether both antigenic stim-
ulation with immune complex and nonspecific B cell stim-
ulation are required for the generation of RF. Earlier
results may be consistent with this idea because polyclonal
B cell stimulation with LPS (5, 6) could induce autoanti-
bodies to multimeric autoantigens or latent viruses such that
unintended immune complexes would develop. With EBV-
stimulated B cells (4), the viral envelope itself could be
complexed with antibodies.
Two classical clinical diseases associated with high titer
RF are subacute endocarditis and RA. In subacute bacterial
endocarditis the culprit is frequently a 
 
Streptococcus.
 
 Once
the offending agent is removed with successful antibiotic
therapy, the RF disappear (19). In RA, the nature of the
stimulus for high titer RF is unknown, but several viruses
have been suggested in the etiology of RA including ru-
bella, lentivirus, parvovirus, and EBV. The original excite-
ment about EBV was due to the description of antibodies,
in sera from RA and Sjögren’s syndrome patients, that
were reactive with EBV-transformed B cell lines (20). Re-
cently the interest in EBV has been revived. When com-
pared with controls, RA patients may have higher levels of
EBV shedding in the throat, increased percentages of in-
fected B cells in the blood, and higher levels of antibodies
to EBV according to some reports. IgG anti-VCA titers to
EBV may correlate with high titers of IgM RF in RA (21).
Reactivation of latent EBV may be associated with a domi-
nant IgG3 anti-VCA response (22). Could this be related to
the suggested isotype specificity of synovial RF in RA? In
four out of nine RA patients, a significant proportion of
synovial fluid CD8 T cells were reactive with HLA-A2–
restricted peptides derived from BMLF1 or BZLF1 (23,
24), early transactivators of EBV that initiate lytic phase vi-
ral replication. Serum antibodies to other lytic phase pro-
teins, BMRF1 and BHRF1, have also been described in a
few patients (25). Contrary to previous reports, we have
obtained clear PCR evidence of EBV viral DNA in syno-
vial tissues in 10 out of 11 patients (J. Edinger, unpublished
data). Moreover, Koide et al. have recently established a
RA synovium derived fibroblastoid cell line (with features
of the synoviocyte type I), which expresses the latency
genes EBNA1, EBNA2, and LMP1 and also expresses early
antigen and viral capsid antigen in a small percentage of
cells (26).
The envelopes of herpesviruses are complicated and pre-
sumably less rigid compared with those of VSV. The icosa-
hedral core (17) is surrounded by a matrix and an envelope
which derives from eukaryotic cell membranes. Future
studies should address the ability of UV-treated EBV com-
plexed with specific antibodies to elicit RF.
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